ACADIA Pharmaceuticals Inc (ACAD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ACADIA Pharmaceuticals Inc stock (ACAD) is currently trading at $22.01. ACADIA Pharmaceuticals Inc PE ratio is 9.11. ACADIA Pharmaceuticals Inc PS ratio (Price-to-Sales) is 3.33. Analyst consensus price target for ACAD is $31.85. WallStSmart rates ACAD as Moderate Buy.
- ACAD PE ratio analysis and historical PE chart
- ACAD PS ratio (Price-to-Sales) history and trend
- ACAD intrinsic value — DCF, Graham Number, EPV models
- ACAD stock price prediction 2025 2026 2027 2028 2029 2030
- ACAD fair value vs current price
- ACAD insider transactions and insider buying
- Is ACAD undervalued or overvalued?
- ACADIA Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ACAD Piotroski F-Score and Altman Z-Score
- ACAD analyst price target and Smart Rating
ACADIA Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
ACAD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · ACADIA Pharmaceuticals Inc (ACAD)
ACAD trades at a significant discount to its Graham intrinsic value of $107.64, offering a 79% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
ACADIA Pharmaceuticals Inc (ACAD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, eps growth, profit margin. Concerns around peg ratio and operating margin. Overall metrics suggest strong investment potential with favorable risk/reward.
ACADIA Pharmaceuticals Inc (ACAD) Key Strengths (5)
Every $100 of shareholder equity generates $40 in profit
Earnings per share surging 86.20% year-over-year
Keeps $37 of every $100 in revenue as net profit
99.59% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
ACADIA Pharmaceuticals Inc (ACAD) Areas to Watch (5)
Very expensive relative to growth, significant premium
Very thin margins with limited operational efficiency
Modest revenue growth at 9.40%
Revenue is fairly priced at 3.33x sales
Fairly priced relative to book value
Supporting Valuation Data
ACADIA Pharmaceuticals Inc (ACAD) Detailed Analysis Report
Overall Assessment
This company scores 66/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Profit Margin. Profitability is solid with Return on Equity at 39.90%, Profit Margin at 36.50%. Growth metrics are encouraging with EPS Growth at 86.20%.
The Bear Case
The primary concerns are PEG Ratio, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (50.86), Price/Sales (3.33), Price/Book (2.88) suggest expensive pricing. Growth concerns include Revenue Growth at 9.40%, which may limit upside. Profitability pressure is visible in Operating Margin at 6.12%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 39.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 9.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, EPS Growth) and negatives (PEG Ratio, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACAD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACAD's Price-to-Sales ratio of 3.33x trades at a deep discount to its historical average of 347.21x (2th percentile). The current valuation is 100% below its historical high of 4688.34x set in Dec 2014, and 2% above its historical low of 3.28x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for ACADIA Pharmaceuticals Inc (ACAD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ACADIA Pharmaceuticals Inc is a mature, profitable business with steady cash generation. Revenue reached 1.1B with 9% growth year-over-year. Profit margins are strong at 36.5%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 39.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -53M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ACADIA Pharmaceuticals Inc.
Bottom Line
ACADIA Pharmaceuticals Inc is a well-established business delivering consistent profitability with 36.5% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ACADIA Pharmaceuticals Inc(ACAD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.